695 completed, 219 terminated, 190 recruiting, 176 unknown. 1476 Phase 2, 412 Phase 1, 53 Phase 3.
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. TJ102 - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Phrontline Biopharma | 150 | 2026-09-29 | 2026-10-21 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-11-02 |
| Finerenone for Premature Ovarian Insufficiency (POI) Finerenone, Placebo - Premature Ovarian Insufficiency | Phase 2 | Not yet recruiting | The University of Hong Kong-Shenzhen Hospital | 46 | 2026-09-15 | 2026-09-11 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch - Turner Syndrome, Primary Ovarian Insufficiency | Phase 2 | Not yet recruiting | Children's National Research Institute | 15 | 2026-09-01 | 2026-08-25 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain Custom-formulated, high-CBD study product, Placebo - Endometriosis, Adenomyosis | Phase 1 / Phase 2 | Recruiting | Staci Gruber, Ph.D. | 60 | 2026-09-01 | 2026-07-27 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NY-ESO-1 Peptide vaccine, Toripalimab-tpzi - Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Phase 2 | Withdrawn | Georgetown University | 2026-09-01 | 2026-10-09 | |
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
Showing 20 of 1476. Sign in to see all of them.
Ovarian Neoplasms (1181) · Fallopian Tube Neoplasms (381) · Carcinoma, Ovarian Epithelial (332) · Breast Neoplasms (160) · Endometrial Neoplasms (135) · Neoplasms (114) · Carcinoma, Non-Small-Cell Lung (101) · Uterine Cervical Neoplasms (100) · Colorectal Neoplasms (97) · Pancreatic Neoplasms (88) · Polycystic Ovary Syndrome (77) · Recurrence (76) · Stomach Neoplasms (76) · Sarcoma (72) · Melanoma (65)
Urogenital Diseases (1476) · Female Urogenital Diseases (1475) · Female Urogenital Diseases and Pregnancy Complications (1475) · Genital Diseases (1475) · Genital Diseases, Female (1469) · Gonadal Disorders (1447) · Endocrine System Diseases (1443) · Ovarian Diseases (1434) · Urogenital Neoplasms (1332) · Genital Neoplasms, Female (1329) · Neoplasms by Site (1329) · Endocrine Gland Neoplasms (1314) · Neoplasms (1308) · Neoplasms by Histologic Type (554)
Carboplatin (210) · Paclitaxel (196) · Bevacizumab (123) · pembrolizumab (73) · Gemcitabine (66) · Cyclophosphamide (56) · Cisplatin (51) · liposomal doxorubicin (51) · olaparib (51) · Topotecan (47) · Docetaxel (37) · niraparib (34) · Taxes (31) · Nivolumab (29) · Filgrastim (28)
National Cancer Institute (NCI) (98) · Gynecologic Oncology Group (36) · M.D. Anderson Cancer Center (30) · Memorial Sloan Kettering Cancer Center (30) · Eli Lilly and Company (19) · AstraZeneca (18) · Dana-Farber Cancer Institute (15) · ARCAGY/ GINECO GROUP (14) · Masonic Cancer Center, University of Minnesota (11) · Mayo Clinic (11) · Fred Hutchinson Cancer Center (10) · Roswell Park Cancer Institute (10) · European Organisation for Research and Treatment of Cancer - EORTC (9) · University Health Network, Toronto (9) · AGO Study Group (8)
United States (832) · China (175) · Canada (137) · Spain (127) · United Kingdom (127) · France (99) · Belgium (89) · Italy (87) · Germany (83) · Australia (77) · South Korea (67) · Netherlands (48) · Israel (39) · Japan (38) · Denmark (36)
Amir A Jazaeri (5) · Amit Oza (5) · Emese Zsiros (5) · Paul Sabbatini, MD (5) · Steven A Rosenberg, M.D. (5) · Ursula Matulonis, MD (5) · Amir Jazaeri, MD (4)
PMID 37185961, PMID 35170751, PMID 37407274, PMID 19238149, PMID 23922302, PMID 26961146, PMID 35537408, PMID 41044356, PMID 18024865, PMID 20609468, PMID 21862407, PMID 22452356, PMID 23810467, PMID 24637997, PMID 24882434, PMID 25218906, PMID 28935273, PMID 31685558, PMID 33337539, PMID 35397664, PMID 36718018, PMID 37496366, PMID 38816232, PMID 39123210, PMID 39695768, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11498213, PMID 11533692, PMID 11705489, PMID 11821109, PMID 11919245, PMID 12065559, PMID 12181243, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12826431, PMID 12957454, PMID 14534883, PMID 14561807
U10CA027469 (34), U10CA180868 (29), 2023 (18), 2009 (11), 2008 (10), 2016 (10), 2015 (8), 2017 (8), 2025 (8), P30CA008748 (8), N01CM62203 (7), 2018 (6), P30CA015083 (6), N01CM00071 (5), N01CM62201 (5)